This study was carried out to investigate whether the personal advocacy of in‰uenza vaccination by community pharmacists to people aged 65 years and above aŠected the vaccination rate and number of in‰uenza patients. A cluster randomized controlled trial was conducted with the cooperation of 84 community pharmacies in the wards of Suginami and Nerima, Tokyo. Participants were aged 65 years and above living in Suginami and Nerima wards, Tokyo, receiving dispensing services in their community pharmacies. The intervention was that pharmacists in the intervention pharmacy group provided information on the risk of in‰uenza and beneˆts of in‰uenza vaccination. Main outcome measures were the self-reported in‰uenza vaccination rate in January 2004, and the number of participants with in‰uenza, as conˆrmed by inspection of their prescriptions from January to May 2004. The vaccination rate in the intervention pharmacy group (81.6％) was signiˆcantly higher than that in the control pharmacy group (64.9％). The number of participants with in‰uenza among the intervention group (2/881) was signiˆcantly lower than that among the control group (11/895). The personal advocacy of in‰uenza vaccination by community pharmacists among people aged 65 years and above increases the vaccination rate and decreases the number of in‰uenza patients.
INTRODUCTION
In‰uenza epidemics usually occur during the winter, and in‰uenza was responsible for an average of 36 000 deaths per year in the United States from 1990 to 1999. 1) Although the rate of in‰uenza infection is the highest among children, serious illness and death following in‰uenza are the most common in elderly people and patients at higher risk for complications. 2 4) Thus, the prevention of in‰uenza infection is an important public health activity among the elderly.
In‰uenza vaccination is eŠective in reducing in‰uenza-related illness, pneumonia, hospitalization, and death among the elderly. 5 7) In Japan, in‰uenza vaccination of people aged 65 years and above has been recommended by the government since 2001 under the reimbursement for in‰uenza vaccination program. Despite that recommendation, the rate of vaccination in that group was 35％ in 2002 2003 season, 8) which was far lower than the government target rate of 60％. 9) Multiple factors contribute to the low vaccination rate, including lack of awareness of the vaccine among the general public and health care workers in Japan. 10) Several studies 11 13) have reported that campaigns by health care workers, including personal and mailed reminders, lead to an increase in vaccination rates. In particular, it was reported that personal reminders by physicians at clinics were more eŠective than reminders by letter. 11) Community pharmacists have many opportunities to contribute to public health through immunization advocacy and to increase their responsibilities in the public-health realm. 12,14 16) Nonetheless, personal advocacy by community pharmacists has not yet been shown to play an important role in increasing vaccine acceptance and decreasing the number of in‰uenza patients. A cluster randomized controlled trial was therefore conducted to determine whether the personal advocacy of in‰uenza vaccination by community pharmacists to people aged 65 years and above aŠected the vaccination rate and number of patients with in‰uenza.
METHOD Study Site and Population
All community pharmacies in the Suginami Pharmaceutical Association and the Nerima Pharmaceutical Association were invited to participate in the study in September 2003. Thirty-nine community pharmacies in the Suginami Pharmaceutical Association and forty-ˆve community pharmacies in the Nerima Pharmaceutical Association agreed to participate in the study. We stratiˆed these community pharmacies into two wards based on the residence (Suginami and Nerima, Tokyo) and three levels based on the number of estimated participants reported from each pharmacy (＜20 participants＝small size pharmacies, 20 to 39 participants＝medium size pharmacies, and 40 to 60 participants＝large size pharmacies). Community pharmacies within each of the six strata were randomly assigned to either the intervention pharmacy or the control pharmacy group.
Participants were recruited from among patients who received dispensing services at the pharmacies. Inclusion criteria were aged 65 years and above and residence in one of the two wards. Exclusion criteria were admission to hospital or nursing home, history of hypersensitivity to the vaccine, and vaccination from October to December in 2003 before receiving the intervention. The study protocol was approved by the Institutional Review Board of Kitasato University School of Pharmacy, and informed consent was obtained from each participant.
Interventions Pharmacists in the intervention pharmacy group displayed two posters, provided participants with information on the risks of in‰uenza and beneˆts of the vaccine in addition to the information in a lea‰et and on the two posters, and physically placed the lea‰et in the hands of the participants. The lea‰et and two posters contained information on in‰uenza susceptibility and severity, vaccine e‹cacy, cost, and sites where vaccinations were available to elderly residents of the two wards.
The personal interventions were conducted from 14 October to 20 December 2003, because in‰uenza vaccinations are usually oŠered from mid-October through late December in Japan, with most people receiving them in November and early December. Each intervention pharmacist was responsible for contacting 5 to 60 participants. To minimize bias, pharmacists in the control pharmacies did not display the two posters, physically place the lea‰et in the hands of the participants, and were speciˆcally requested to avoid initiating any discussion of vaccination with participants. If, however, their participants inquired about an in‰uenza vaccination, the pharmacists were free to discuss vaccination opportunities.
Outcome Measures Data were collected through a baseline survey and two follow-up surveys. After the provision of information on the purpose of the study and obtaining informed consent from participants, the baseline survey was conducted, which included questions regarding age, gender, and in‰uenza vaccination status in the year prior to the study ( The primary outcome measures were the selfreported in‰uenza vaccination rate by community pharmacies and the number of participants who had had in‰uenza by community pharmacies, as conrmed by the inspection of their prescriptions. The secondary outcome measure was the self-reported in‰uenza-associated hospitalization (in‰uenza or pneumonia hospitalization) rate by community pharmacies from January to May 2004.
The number of participants with in‰uenza was dened as those with prescriptions for neuraminidase inhibitor antiviral drugs (oseltamivir or zanamivir), because those agents had not been approved for prophylaxis in Japan during this study period.
Statistical Analysis It was estimated that 712 participants in the study area divided into two groups of equal size would provide at least 80％ power to detect a 10％ diŠerence in the proportions of participants receiving a recommended vaccination, given the vaccination rate 30％ in a control pharmacy, 40％ in a intervention pharmacy, 17) and a＝0.05. With an anticipated dropout rate of approximately 20％ and cluster design eŠect of 10％, 18) 940 participants in the study area (total 1880 participants) were speciˆed to provide an adequate number of evaluable participants. An intention-to-treat analysis was performed on all participants to determine the vaccination rate. To determine the number of participants who had in‰uenza and in‰uenza-associated hospitalization, analyses included only the 1776 participants who completed both surveys. Baseline characteristics and follow-up data between the two groups or wards of residence were compared using the weighted t-test 19) for proportions (gender, prior vaccination status, and current vaccination status), the chi-square for the other proportions (the number of in‰uenza patients and in‰uenza-associated hospitalization), and the t-test for the continuous variable (age).
RESULTS
A total of 1863 participants (911 in the intervention pharmacy group and 952 in the control pharmacy group) and 84 community pharmacies (40 in the intervention pharmacy group and 44 in the control pharmacy group) were included in this study (Fig.  1) . Eighty-seven participants (4.7％) (30 in the intervention pharmacy group and 57 in the control pharmacy group) andˆve community pharmacies (four in the intervention pharmacy group and one in the control pharmacy group) were lost to follow-up. Age, gender, and prior vaccination status did not diŠer signiˆcantly between the two groups ( Table 1) .
The current vaccination rate in the intervention pharmacy group (81.6％) was signiˆcantly higher than that in the control pharmacy group (64.9％) (p ＜0.001) ( Table 2 ). The absolute rate diŠerence was 16.7％ (Nerima, 19.5％; Suginami, 13.7％). The mean diŠerence in the change to vaccination uptake rate between the intervention and control pharmacy groups was 8.7％ (95％CI＝2.2 15.2％).
Additionally, the diŠerences in participant characteristics and current-year vaccination rate between the two wards were analyzed. The characteristics of participants did not diŠer between the two, but the current vaccination rate in Suginami was higher than that in Nerima (7.0％ in control pharmacy group and 1.2 ％ in intervention pharmacy group).
To determine the number of participants who had in‰uenza and required in‰uenza-associated hospitalization, the 1776 participants who completed the two follow-up surveys were analyzed. The number of participants with in‰uenza in the intervention pharmacies (2/881) was signiˆcantly lower than that in the control pharmacies (11/895) (p＝0.022). The relative risk (RR) of having in‰uenza in the intervention group compared with the control pharmacy group was 0.18 (95％CI＝0.04 0.83). No participants with in‰uenza-associated hospitalization were observed in the intervention and control pharmacy groups.
DISCUSSION
The personal advocacy of in‰uenza vaccination by a community pharmacist to people aged 65 years and above was eŠective in increasing the vaccination rate and thereby decreasing the number of patients with in‰uenza. To the authors' knowledge, this is theˆrst outcome study to conˆrm the eŠectiveness of personal advocacy.
The increased vaccination rate after intervention (16.7％) was higher than that reported for senior center-based reminder letters (11.2％), 13) communitybased reminder letters (8.8％), 17) and community pharmacy-based reminder letters (10.3％). 12) Compared with interventions by mail, 12, 13, 17) intervention that included displaying posters in pharmacies, a personal talk in addition to the display of a lea‰et and posters, and handing the lea‰et to the participants might have given patients a more extensive understanding of in‰uenza vaccination. As it required aboutˆve minutes per participant to conduct the intervention, it did not disrupt the pharmacists' daily work. Thus, the intervention described here is replicable with little adaptation by other community pharmacists. In addition to increasing the vaccination rate, the intervention resulted in a decrease in the number of patients with in‰uenza. However, the present study was not able to show that the increased vaccination rate resulted in fewer in‰uenza-associated hospitalizations, because no participant with in‰uenza-associated hospitalization was observed in the intervention pharmacy and the control pharmacy groups. Several studies 12 14,20) reported that campaigns by health care workers lead to an increase in vaccination rates and a corresponding decrease in the number of in‰uenza patients and in‰uenza-associated hospitalizations.
Grabenstein et al. 14) estimated that an increase of 10.3 ％ in the vaccination rate due to a pharmacy-based reminder letter would prevent 1514 cases of in‰uenza and 64 in‰uenza-associated hospitalizations per 100 000 persons aged 65 years and above. The increased vaccination rate after the intervention in the present study (16.7％) was about 1.6-fold higher than that reported by Grabenstein et al. 14) Based on these data, it is estimated that the increased vaccination rate after intervention in the present study would prevent 102 in‰uenza-associated hospitalizations per 100 000 persons, and therefore 1.8 in‰uenza-associated hospitalizations might be prevented among the 1776 participants who completed the two follow-up surveys. This suggests that the lack of a demonstration of in‰uenza-associated hospitalization might be due to insu‹cient power of detection. Future research is required to determine whether the increasing in‰uenza vaccination rate after intervention resulted in a decrease in in‰uenza-associated hospitalizations.
During this study period, participants in Suginami received a reminder letter about in‰uenza vaccination from the ward o‹ce, but participants in Nerima did not. The reminder letter contained information on in‰uenza susceptibility, vaccine costs, and vaccination sites available to senior residents. Previous studies 11 13) showed that reminder letters increase the vaccination rate. To avoid potential bias due to the Suginami reminder letter, the results were stratiˆed by ward of residence. The eŠect of intervention on the in‰uenza vaccination rate was greater in Nerima (19.6％) than in Suginami (13.7％). It is thus thought that the eŠect of intervention in Suginami might be underestimated due to the reminder letter. However, the intervention signiˆcantly increased the vaccination rate not only in Nerima but also in Suginami. This suggests that personal intervention by a community pharmacist may succeed in reaching elderly nonresponders better than other vaccination promotion activities (newsletter articles, media announcements, and reminder letter from the ward o‹ce) and may be an eŠective addition to current immunization promotion strategies.
One limitation of this study is that participants were recruited from among patients who received dispensing services from pharmacies and may have been more motivated to receive in‰uenza vaccinations. The prior vaccination rate in our study (61.3％ in the intervention pharmacy group and 53.3％ in the control pharmacy group) was considerably higher than that observed among all people aged 65 years and above in the two wards (28.5％ in 2002 2003 season). The high vaccination rate in this study may be attributed to greater awareness of disease prevention because of high-risk medical conditions among the senior population who use prescribed medicines than among the general senior population. 12) Thus, participants may not have been representative of the senior population in general.
The second limitation is that the intervention relied on participants visiting a community pharmacy during the vaccination season. The Japanese government reported that the number of people aged 65 years and above was 24 224 000 21) in 2003 and that about onehalf visited a community pharmacy in the vaccination season. 22) Thus, the present results may be generalizable to about 50％ of all Japanese people aged 65 years and above. In contrast, the reminder letter from the ward o‹ce did not rely on patients making visits during the vaccination season. Accordingly, it is believed that the combination of the reminder letter from the ward o‹ce and intervention by a community pharmacist may be the best strategy for increasing the vaccination rate.
The third limitation is that vaccination status was ascertained by self-report, which may not accurately re‰ect vaccinations received. However, several investigators have reported good agreement between selfreported receipt of in‰uenza vaccination and medical record audits. 22 26) It is therefore thought that the self-reported in‰uenza vaccination rate accurately re‰ects the true vaccinations received.
The fourth limitation is that the vaccine for the 2003 2004 season contained the in‰uenza virus antigens A/New Caledonia/20/99 (H1N1), A/Panama/ 2007/99 (H3N2), and B/Shandong/7/97, which were not similar to the in‰uenza viruses isolated during this study. 27) In‰uenza vaccine e‹cacy varies depending on the similarity of the vaccine strains to the circulating strain. 4, 28) The decrease in the number of patients with in‰uenza as a result of the increased vaccination rate after the intervention in this study might thus be underestimated.
In conclusion, the personal advocacy of in‰uenza vaccination by a community pharmacist to people aged 65 years and above is eŠective in increasing the in‰uenza vaccination rate and thereby decreasing the number of in‰uenza patients.
